Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer

NCT03395899 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT03395899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03395899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Completed
Start date
December 21, 2017
Completion date
August 18, 2023
Enrollment
71 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, estrogen receptor-positive breast cancer